DK1434570T3 - Farmaceutiske formuleringer til kontrolleret frigivelse af 4-amino-6,7-dimethoxy-2-(5-methansulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazolin - Google Patents

Farmaceutiske formuleringer til kontrolleret frigivelse af 4-amino-6,7-dimethoxy-2-(5-methansulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazolin

Info

Publication number
DK1434570T3
DK1434570T3 DK02775048T DK02775048T DK1434570T3 DK 1434570 T3 DK1434570 T3 DK 1434570T3 DK 02775048 T DK02775048 T DK 02775048T DK 02775048 T DK02775048 T DK 02775048T DK 1434570 T3 DK1434570 T3 DK 1434570T3
Authority
DK
Denmark
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
quinazoline
dimethoxy
pyridyl
Prior art date
Application number
DK02775048T
Other languages
English (en)
Inventor
John D Davis
Michael J Humphrey
Ross J Macrae
Janet S Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1434570T3 publication Critical patent/DK1434570T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02775048T 2001-10-11 2002-09-30 Farmaceutiske formuleringer til kontrolleret frigivelse af 4-amino-6,7-dimethoxy-2-(5-methansulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazolin DK1434570T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK1434570T3 true DK1434570T3 (da) 2005-11-07

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02775048T DK1434570T3 (da) 2001-10-11 2002-09-30 Farmaceutiske formuleringer til kontrolleret frigivelse af 4-amino-6,7-dimethoxy-2-(5-methansulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazolin

Country Status (33)

Country Link
EP (1) EP1434570B8 (da)
JP (1) JP4131471B2 (da)
KR (1) KR20050032510A (da)
CN (1) CN1568180A (da)
AP (1) AP2004003001A0 (da)
AR (1) AR036782A1 (da)
AT (1) ATE303135T1 (da)
BR (1) BR0213196A (da)
CA (1) CA2461168A1 (da)
CO (1) CO5560534A2 (da)
DE (1) DE60205925T2 (da)
DK (1) DK1434570T3 (da)
DO (1) DOP2002000464A (da)
EA (1) EA006168B1 (da)
ES (1) ES2246017T3 (da)
GB (1) GB0124455D0 (da)
GT (1) GT200200184A (da)
HR (1) HRP20040261A2 (da)
HU (1) HUP0600064A3 (da)
IL (1) IL160969A0 (da)
IS (1) IS7179A (da)
MA (1) MA27075A1 (da)
MX (1) MXPA04003293A (da)
NO (1) NO20041520L (da)
OA (1) OA12709A (da)
PA (1) PA8556001A1 (da)
PE (1) PE20030551A1 (da)
PL (1) PL369666A1 (da)
PY (1) PY0223360A (da)
SV (1) SV2004001279A (da)
UY (1) UY27477A1 (da)
WO (1) WO2003032956A1 (da)
ZA (1) ZA200401976B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
EP3821882A1 (en) 2013-03-14 2021-05-19 Amgen Inc. Heterocyclic compounds and their uses
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466986B1 (en) * 1990-07-02 1994-04-27 Bend Research, Inc. Asymmetric microporous beads for controlled release
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
AU779118B2 (en) * 2000-03-03 2005-01-06 Pfizer Inc. 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3, 4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylate and polymorphs

Also Published As

Publication number Publication date
ES2246017T3 (es) 2006-02-01
EP1434570B8 (en) 2005-10-26
MXPA04003293A (es) 2004-07-23
UY27477A1 (es) 2003-05-30
EA200400431A1 (ru) 2004-08-26
CO5560534A2 (es) 2005-09-30
HRP20040261A2 (en) 2004-08-31
AP2004003001A0 (en) 2004-03-31
DOP2002000464A (es) 2003-04-15
BR0213196A (pt) 2004-08-31
PL369666A1 (en) 2005-05-02
IL160969A0 (en) 2004-08-31
EP1434570B1 (en) 2005-08-31
SV2004001279A (es) 2004-02-19
CN1568180A (zh) 2005-01-19
IS7179A (is) 2004-03-11
NO20041520L (no) 2004-04-05
AR036782A1 (es) 2004-10-06
DE60205925T2 (de) 2006-06-08
CA2461168A1 (en) 2003-04-24
GT200200184A (es) 2003-05-23
DE60205925D1 (de) 2005-10-06
OA12709A (en) 2006-06-26
PE20030551A1 (es) 2003-06-26
HUP0600064A2 (en) 2006-06-28
EP1434570A1 (en) 2004-07-07
ATE303135T1 (de) 2005-09-15
EA006168B1 (ru) 2005-10-27
WO2003032956A1 (en) 2003-04-24
MA27075A1 (fr) 2004-12-20
GB0124455D0 (en) 2001-12-05
JP2005507909A (ja) 2005-03-24
PA8556001A1 (es) 2003-07-28
JP4131471B2 (ja) 2008-08-13
ZA200401976B (en) 2004-07-12
PY0223360A (es) 2004-04-01
HUP0600064A3 (en) 2007-02-28
KR20050032510A (ko) 2005-04-07

Similar Documents

Publication Publication Date Title
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
IS7227A (is) Salt form af E-2-metoxí-N-(3-(4-(3-metýl-pýridín-3-yloxýl)-fenýlamínó)-kínasólín-6-yl)-allýl)-asetamíð, framleiðsla þess og notkun gegn krabbameini
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
DK1762567T3 (da) Pyrazolderivater til behandling af HIV
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
DK1417180T3 (da) Fremstilling af aminopyrimidinforbindelser
IS6968A (is) Nýir týrósínkínasa tálmar
DZ3425A1 (fr) Derives de quinolinone en tant qu'inhibiteurs kinases de tyrosine
DK1202746T3 (da) NSAID- og EGFR-kinaseinhibitorerholdigt præparat til behandling eller inhibering af colonpolypper og colorektal cancer
DK1408756T3 (da) Fremgangsmåde til bekæmpelse af ukrudt
NO20035540D0 (no) Eksoterme preparater til behandling av ektoparasitter
DK1458386T3 (da) Aroylpyrrolheteroaryl- og methanolforbindelser til behandling af en lidelse i centralnervesystemet
NO20024195D0 (no) 4-amino-6,7-dimetoksy-2-(5-metansulfonamido-1,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridinyl)quinazolin-mesylat samtpolymorfer
NO20041520L (no) Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
DK1244359T3 (da) Kombination af fluazuron og ivermectin til kontrol af parasitter
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
DK1345605T3 (da) Varmformet lægemiddelsammensætning til styret afgivelse af perindopril
DK1451177T3 (da) Substituerede 2-pyrrolidin-2-yl-1H-indol-derivater til behandling af migræne
DK1534672T3 (da) Retinolderivater, deres anvendelse til behandling af cancer og til potensering af virkningen af andre cytotoksi¬ske midler
DK1153015T3 (da) Pyrimidin-2,4,6-trioner som inhibitorer af matrix-metalloproteinaser
DK1335730T3 (da) Anvendelse af PDE5-inhibitorer til behandling af ejaculatio praecox
DK1350794T3 (da) Fremgangsmåde til fremstilling af substans GM-95